Early-onset liver fibrosis due to primary hepatitis c virus infection is higher over time in HIV-infected men

Daniel S. Fierer; Michael P. Mullen; Douglas T. Dieterich; M. Isabel Fiel; Andrea D. Branch

doi:10.1093/cid/cis538

Early-onset liver fibrosis due to primary hepatitis c virus infection is higher over time in HIV-infected men

Research output: Contribution to journal › Letter › peer-review

14 Scopus citations

Original language	English
Pages (from-to)	887-888
Number of pages	2
Journal	Clinical Infectious Diseases
Volume	55
Issue number	6
DOIs	https://doi.org/10.1093/cid/cis538
State	Published - Sep 2012

Access to Document

10.1093/cid/cis538

Cite this

@article{3f2474105f6145bfaef9358a6abc394a,

title = "Early-onset liver fibrosis due to primary hepatitis c virus infection is higher over time in HIV-infected men",

author = "Fierer, \{Daniel S.\} and Mullen, \{Michael P.\} and Dieterich, \{Douglas T.\} and \{Isabel Fiel\}, M. and Branch, \{Andrea D.\}",

note = "Funding Information: received institutional grant support from the National Institutes of Health. D. T. D. has received institutional grant support from Genen-tech; consulting fees from Genentech, Roche, Boehringer Ingelheim, Idenix, Bristol-Myers Squibb, and Gilead; and fees for participation in review acivities from Tobira. All other authors report no potential conflicts.",

year = "2012",

month = sep,

doi = "10.1093/cid/cis538",

language = "English",

volume = "55",

pages = "887--888",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Early-onset liver fibrosis due to primary hepatitis c virus infection is higher over time in HIV-infected men

AU - Fierer, Daniel S.

AU - Mullen, Michael P.

AU - Dieterich, Douglas T.

AU - Isabel Fiel, M.

AU - Branch, Andrea D.

N1 - Funding Information: received institutional grant support from the National Institutes of Health. D. T. D. has received institutional grant support from Genen-tech; consulting fees from Genentech, Roche, Boehringer Ingelheim, Idenix, Bristol-Myers Squibb, and Gilead; and fees for participation in review acivities from Tobira. All other authors report no potential conflicts.

PY - 2012/9

Y1 - 2012/9

UR - https://www.scopus.com/pages/publications/84865494730

U2 - 10.1093/cid/cis538

DO - 10.1093/cid/cis538

M3 - Letter

C2 - 22677713

AN - SCOPUS:84865494730

SN - 1058-4838

VL - 55

SP - 887

EP - 888

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -